VivaTech 2019: Thales Receives Global Innovator Award and Invites Visitors to Be Astronauts for a Day
7.5.2019 08:00:00 EEST | Business Wire | Press release
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190506005645/en/
"Thales Alenia Space". Copyright: Thales
Global recognition for research and innovation
The Derwent Top 100 Global Innovators ranking recognises the volume, success and influence of the patents filed by technology companies. Thales has appeared six times in this prestigious ranking, reflecting the company’s commitment to innovating, bringing inventions to market and protecting its ideas.
This distinction comes at a turning point in Thales’s history. With the completion of the acquisition of Gemalto on 2 April, the Group now employs 28,000 engineers, devotes €1 billion a year to self-funded R&D and maintains a portfolio of 20,500 patents, including 400 filed in 2018. At the show, Thales will also sign the LGBT+ Charter championed by Autre Cercle, thus highlighting the group’s strategy of promoting diversity and inclusion across its talent pool, as a way to free creative potential and foster innovation.
Thales at VivaTech: AI for every decisive moment
Thales will be showcasing its latest innovations alongside some 30 start-ups from six countries specialising in artificial intelligence, connectivity, drone technology, cybersecurity and robotics.
A series of demonstrations will show how advanced technology helps real-life users to understand the most complex situations:
- Columbus invites visitors to feel what it’s like to be an astronaut on-board the International Space Station’s science laboratory.
- The autonomous train demonstrator lets visitors drive a New York City subway train and see how they match up to the capabilities of artificial intelligence.
- Piume allows users to experience what it’s like to be an explorer or a researcher working in harsh environments.
- Geonav uses the Galileo satellite constellation to prevent risks faced by high-level athletes, without the dropped signals that often occur inside sports stadiums.
- Smart New World combines the power of holographic displays with IoT (Internet of Things) technology.
- The 3D interactive hologram table developed with the Australian start up Euclideon models anything you can imagine: cities, objects, design techniques and much more.
Thales experts will also be taking part in around 40 panel sessions to discuss how artificial intelligence that is trustable, explainable and certifiable can be used to invent or reinvent the cities of the future, develop autonomous trains and future medical imaging solutions, protect the environment and take space exploration to the next frontier. The schedule for the demonstrations and panel sessions can be found on the Thales event website.
Thales Decisive Journeys at VivaTech
- DecisiveJourney#1: From space observation to personal data protection: find out how trusted AI is a decisive technology for Thales
- DecisiveJourney#2: Thales technologies applied to environmental protection
- DecisiveJourney#3: Artificial nano-neurons and medical imaging: Thales innovations reshaping the future of medicine
- DecisiveJourney#4: How to develop responsible AI
- DecisiveJourney#5: How digital is changing our companies and work methods
About Thales
The people we all rely on to make the world go round – they rely on Thales. Our customers come to us with big ambitions: to make life better, to keep us safer. Combining a unique diversity of expertise, talents and cultures, our architects design and deliver extraordinary high technology solutions. Solutions that make tomorrow possible, today. From the bottom of the oceans to the depth of space and cyberspace, we help our customers think smarter and act faster - mastering ever greater complexity and every decisive moment along the way. With 80,000 employees in 68 countries, Thales reported sales of €19 billion in 2018
PLEASE VISIT
Thales
Group
Twitter: @Thalesgroup
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190506005645/en/
Contact information
Thales, Media Relations
Alice Pruvot +33 (0)7 70 27 11 37
alice.pruvot@thalesgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom